Bioton S.A. Claim profile
ISIN: PLBIOTN00029 | Ticker: BIO | LEI: 259400I5R1L3OPCGII81
BIOTON is an innovative Polish biotechnology company, which provides patients with safe and complete solutions for diabetes care. Bioton is an unquestionable leader on the Polish market, and in the world’s top eight commercial manufacturers of recombinant human insulin.
Bioton continuously invests in the development of Polish biotechnology. We are the first and only company in Poland which is able to fully translate its technology into commercial use.
Recombinant human insulin is an efficient and safe therapy for most people suffering from diabetes. We strive to become the provider of complete diabetes care solutions and the preferred choice for patients, doctors and the diabetes community.
1989
Served areaWorldwide
HeadquartersStarościńska 5, 02-516 Warszawa – Poland
| Report | Q1 | H1 | Q3 | FY |
|---|---|---|---|---|
| Consolidated Report | pl | |||
| Corporate Governance Report | ||||
| Company Presentation | ||||
| General Presentation | ||||
| Sustainability Report | ||||
| Remuneration Report |
| Report | Q1 | H1 | Q3 | FY |
|---|---|---|---|---|
| Consolidated Report | pl | |||
| Corporate Governance Report | ||||
| Company Presentation | ||||
| General Presentation | ||||
| Sustainability Report | ||||
| Remuneration Report |
85,864,200
IPOMarch 1, 2005
Stock exchange(s)Warsaw Stock Exchange
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.